## Torrent Pharmaceuticals Limited (TORNTPHARM) Stock Analysis

This report analyzes Torrent Pharmaceuticals Limited (TORNTPHARM) stock based on the provided data.  The analysis focuses on key indicators to determine whether the stock is a buy, sell, or hold.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Feature          | Value                     |
|-----------------|--------------------------|
| Symbol           | TORNTPHARM                |
| Company Name     | Torrent Pharmaceuticals Limited |
| Industry         | Pharmaceuticals           |
| Listing Date     | 2002-11-25                |
| ISIN             | INE685A01028              |


**1.2 Market Data (as of 20-Dec-2024):**

| Metric                | Value       |
|-----------------------|-------------|
| Last Price            | 3439.95     |
| Change                | -29.20      |
| % Change              | -0.84%      |
| Previous Close        | 3469.15     |
| Open                  | 3476.25     |
| Close                 | 3437.00     |
| VWAP                  | 3476.61     |
| Week High             | 3590.70     |
| Week Low              | 2113.80     |
| Sector PE             | 67.92       |
| Symbol PE             | 65.16       |
| Intraday High        | 3515.35     |
| Intraday Low         | 3421.40     |
| Delivery to Traded % | 49.21%      |
| Total Traded Volume  | 358325      |


**1.3 Corporate Actions:**

| Ex-Date      | Purpose                               |
|--------------|---------------------------------------|
| 21-Jun-2024  | Dividend - Rs 6 Per Share             |
| 12-Feb-2024  | Interim Dividend - Rs 22 Per Share    |
| 23-Jun-2023  | Dividend - Rs 8 Per Share             |
| 03-Feb-2023  | Interim Dividend - Rs 14 Per Share    |
| 08-Jul-2022  | Bonus 1:1                             |
| 02-Feb-2022  | Interim Dividend - Rs 25 Per Share    |
| 17-Jun-2021  | Dividend - Rs 15 Per Share             |
| 15-Feb-2021  | Interim Dividend - Rs 20 Per Share    |
| ...           | ...                                   |  *(Further historical data available)*


**1.4 Recent Announcements (Last 8):**

| Broadcast Date | Subject                                      |
|-----------------|----------------------------------------------|
| 19-Dec-2024    | Updates                                       |
| 09-Dec-2024    | Copy of Newspaper Publication                 |
| 04-Dec-2024    | Press Release                                  |
| 28-Nov-2024    | Action(s) initiated or orders passed          |
| 27-Nov-2024    | Loss/Duplicate-Share Certificate-XBRL         |
| 27-Nov-2024    | Loss of Share Certificates                     |
| 27-Nov-2024    | Loss/Duplicate-Share Certificate-XBRL         |
| 27-Nov-2024    | Loss of Share Certificates                     |


**1.5 Financial Results (Last Five Quarters):**

| Quarter      | Income (₹) | Expenditure (₹) | Profit After Tax (₹) | EPS (₹) |
|--------------|------------|-----------------|-----------------------|---------|
| Q2 FY25      | 242,700    | 175,700          | 46,000                | 13.6    |
| Q1 FY25      | 245,900    | 179,200          | 46,900                | 13.86   |
| Q4 FY24      | 221,900    | 168,900          | 41,000                | 12.12   |
| Q3 FY24      | 211,200    | 168,200          | 29,700                | 8.78    |
| Q2 FY24      | 216,100    | 167,900          | 32,700                | 9.65    |


**1.6 Shareholding Patterns:**

Promoter holding has remained consistently at 71.25% over the last four quarters.  Public shareholding is at 28.75%.  No significant changes are observed.


**1.7 Board Meetings:**

Recent board meetings focused on approving financial results and other business matters.  No unusual activity is noted.


**1.8 Key Management Personnel & Contact Information:**

*(Details available in the provided data, but omitted here for brevity.  This information is readily accessible in the original data.)*


**2. Key Indicators:**

**2.1 Current Price Analysis:**

* The current price (3439.95) is lower than the previous close (3469.15), indicating a downward trend.
* It's also below the intraday high (3515.35) and significantly below the week high (3590.70).
* The pre-open price (3476.25) was higher than the closing price, suggesting some selling pressure during the trading session.

**2.2 Financial Performance:**

* Revenue shows some fluctuation but generally remains stable over the last five quarters.
* Profit after tax and EPS show some variability, with a dip in Q3 FY24.  Overall, profitability is positive.

**2.3 Shareholding Analysis:**

* Promoter holding remains stable at 71.25%, indicating strong management confidence.

**2.4 Corporate Action Summary:**

* The company has a history of consistent dividend payouts and a recent bonus issue (1:1 in 2022), suggesting a shareholder-friendly approach.

**2.5 Volatility and Risk:**

* The CM Daily Volatility (1.48) and CM Annual Volatility (28.28) need to be compared to industry benchmarks to assess the risk level accurately.  Without benchmarks, a definitive statement on volatility cannot be made.

**3. Final Verdict:**

Based solely on the provided data, the recommendation is **Hold**.

**Reasoning:**

* While the recent price action shows a slight downward trend, the company demonstrates consistent profitability and a history of rewarding shareholders through dividends and bonus issues.  The stable promoter holding is a positive sign.  However, the lack of comparative volatility data prevents a stronger recommendation.  Further investigation into industry benchmarks for volatility and a deeper dive into the nature of recent announcements is recommended before making a buy decision.

**Conclusion:**

Torrent Pharmaceuticals shows signs of financial stability and a commitment to shareholder returns.  However, the current price movement and limited volatility data suggest a cautious approach.  A "Hold" recommendation is appropriate pending further analysis.  More information on the nature of recent announcements and comparative market data would allow for a more confident assessment.
